Equity Mutual Fund Inflows Jump To 8-Month High Of ₹40,450 C...
10 Apr 2026
Novartis AG, the Swiss pharmaceutical major and promoter of Novartis India Limited, has filed a mandatory regulatory disclosure with BSE Limited confirming the non-encumbrance status of its equity holdings and reiterating details of its previously announced divestment agreement.
Share Encumbrance Declaration
In compliance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Novartis AG declared that it has not created any encumbrance on its equity shares in Novartis India Limited, either directly or indirectly, as of March 31, 2026.
Parameter: Details Total Equity Shares Held: 1,74,50,680 Shareholding Percentage: 70.68% Encumbrance Status: No encumbrance Declaration Date: March 31, 2026
Sale Agreement Confirmation
The disclosure reaffirmed the sale and purchase agreement (SPA) entered into on February 19, 2026, for the complete divestment of Novartis AG's stake in its Indian subsidiary. The transaction involves three strategic acquirers who will collectively acquire the entire promoter holding.
Acquirer Details
The sale agreement encompasses three distinct entities:
WaveRise Investments Limited (Acquirer 1)
ChrysCapital Fund X (Acquirer 2)
Two Infinity Partners (Acquirer 3)
Transaction Parameter: Specification Total Shares for Sale: 1,74,50,680 Stake Percentage: 70.68% Agreement Date: February 19, 2026 Number of Acquirers: 3
Regulatory Compliance
The filing demonstrates Novartis AG's adherence to Indian securities regulations governing substantial shareholding transactions. The disclosure was addressed to BSE Limited and copied to the Audit Committee of Novartis India Limited, ensuring comprehensive regulatory notification.
The document was signed by authorized signatories Lukas Förtsch and Stefan Thommen, representing Novartis AG's commitment to maintaining transparency throughout the divestment process. This regulatory filing provides stakeholders with updated information on the transaction's progress and confirms the integrity of the shareholding structure pending completion of the sale.
Novartis India Limited has officially announced a Board of Directors meeting scheduled for May 12, 2026, to review and approve the company's audited financial results for the fourth quarter and full financial year ended March 31, 2026. The announcement was made through a formal communication to BSE Limited on March 31, 2026, in compliance with regulatory requirements.
Board Meeting Details
The pharmaceutical company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will focus on considering and approving the audited financial results for Q4FY26.
Meeting Details: Information Date: Tuesday, May 12, 2026 Purpose: Consider and approve audited financial results Period Covered: Quarter and financial year ended March 31, 2026 Regulatory Compliance: SEBI (LODR) Regulations, 2015 - Regulation 29 BSE Scrip Code: 500672
Trading Window Closure
In connection with the upcoming board meeting, Novartis India Limited has announced the closure of its trading window for designated persons, insiders, connected persons, and their immediate relatives. This measure ensures compliance with insider trading regulations and maintains market integrity.
Trading Window Parameters: Details Closure Date: Wednesday, April 1, 2026 Applicable To: Designated Persons/Insiders/Connected Persons and immediate relatives Reopening: 48 hours after financial results declaration to stock exchange Regulatory Framework: SEBI (Prohibition of Insider Trading) Regulations, 2015
Corporate Governance and Compliance
The trading window closure is implemented pursuant to the company's 'Code of Conduct to regulate, monitor and report share trading by Designated Persons/Insiders/Connected Persons and their immediate relatives.' This code operates in conjunction with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.
The communication was digitally signed by Chandni Maru, Company Secretary and Compliance Officer, emphasizing the company's commitment to maintaining transparency and regulatory compliance in its corporate governance practices. The company is headquartered at Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.
